Trial Profile

The purpose of this phase I/Ib study was to determine the safety profile of NIZ985 (new formulation), and if it could be safely combined with spartalizumab or tislelizumab and to determine the appropriate dose and schedule for further study. Moreover, the study characterized the pharmacokinetic profiles of NIZ985 as a single agent and in combination with spartalizumab or tislelizumab and identified preliminary anti-tumor activity

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interleukin-15 (Primary) ; Spartalizumab (Primary) ; Tislelizumab (Primary)
Indications Lymphoma; Malignant melanoma; Non-small cell lung cancer; Skin cancer; Solid tumours
Focus Adverse reactions
Sponsors Novartis Pharmaceuticals

11 Jan 2024 Status changed from active, no longer recruiting to discontinued.
02 Jan 2024 Planned End Date changed from 5 Jan 2024 to 16 Jan 2024.
02 Jan 2024 Planned primary completion date changed from 5 Jan 2024 to 16 Jan 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com